

AMENDMENT TO RULES COMM. PRINT 119–33
OFFERED BY MRS. BIGGS OF SOUTH CAROLINA

At the end of subtitle A of title XVII, insert the following:

1 **SEC. 17___ . COUNTERING BIOTECHNOLOGY THREATS**
2 **FROM THE PEOPLE’S REPUBLIC OF CHINA.**

3 (a) SENSE OF CONGRESS.—It is the sense of Con-
4 gress that—

5 (1) the rapid advancement of the People’s Re-
6 public of China in biotechnology, including gene-edit-
7 ing, synthetic biology, and dual-use technologies,
8 poses a significant threat to the national security of
9 the United States and its military superiority;

10 (2) China’s military-civil fusion strategy inte-
11 grates civilian biotechnology research with military
12 applications, potentially enabling the development of
13 enhanced soldier capabilities, bioweapons, and other
14 asymmetric threats;

15 (3) China’s dominance in global biotechnology
16 supply chains and its strategic investments in
17 United States biotechnology firms risk undermining
18 United States innovation, security, and access to
19 critical resources;

1 purposes, development of biological agents, and abil-
2 ity to disrupt international and United States supply
3 chains critical to military operations;

4 “(2) strategies to counter such threats, includ-
5 ing investments in United States biotechnology re-
6 search and development, supply chain resilience, and
7 defensive biotechnological capabilities; and

8 “(3) coordination with allies and international
9 partners to address biotechnology-related national
10 security risks.

11 “(c) The Secretary of Defense shall develop the strat-
12 egy required by this section in consultation with the Sec-
13 retary of State, the Secretary of Health and Human Serv-
14 ices, the Secretary of Homeland Security, the Director of
15 National Intelligence, defense and technology industry
16 partners, research and development partners, other Fed-
17 eral research agencies, allies and partners of the United
18 States, and other appropriate organizations.

19 “(d)(1) The Secretary of Defense shall submit to the
20 appropriate congressional committees a report, in unclas-
21 sified form but which may contain a classified annex, that
22 includes the strategy developed pursuant to subsection (a).

23 “(2) In this subsection, the term ‘appropriate con-
24 gressional committees’ means—

1 “(A) the Committee on Armed Services, the
2 Committee on Foreign Relations, the Committee on
3 Commerce, Science, and Transportation, and the
4 Committee on Banking, Housing, and Urban Affairs
5 of the Senate; and

6 “(B) the Committee on Armed Services, the
7 Committee on Foreign Affairs, the Committee on
8 Energy and Commerce, and the Committee on Fi-
9 nancial Services of the House of Representatives.”.

10 (c) ASSESSMENT OF CHINA’S USE OF BIO-
11 TECHNOLOGY FOR MILITARY MODERNIZATION.—

12 (1) IN GENERAL.—Not later than 180 days
13 after the date of the enactment of this Act, the Di-
14 rector of National Intelligence, in consultation with
15 the Director of the Central Intelligence Agency, the
16 Secretary of Commerce, and the Secretary of De-
17 fense, shall submit to the appropriate congressional
18 committees a comprehensive assessment of the Peo-
19 ple’s Republic of China’s use of biotechnology for
20 military modernization.

21 (2) ELEMENTS OF ASSESSMENT.—The assess-
22 ment required under paragraph (1) shall include—

23 (A) an evaluation of China’s biotechnology
24 research and development programs with poten-

1 tial military applications, including gene-edit-
2 ing, synthetic biology, and bioinformatics;

3 (B) an analysis of China's military-civil fu-
4 sion strategy and its impact on advancing mili-
5 tary biotechnology capabilities;

6 (C) an assessment of the potential for
7 China to develop biological weapons or other
8 asymmetric biotechnological threats;

9 (D) an assessment of Chinese entities, in-
10 cluding private companies, state-owned enter-
11 prises, and government bodies, that are devel-
12 oping dual-use biotechnology and any depend-
13 encies they have on United States or other for-
14 eign technology, components, or services;

15 (E) an evaluation of China's control over
16 global biotechnology supply chains and the im-
17 plications for United States military readiness;
18 and

19 (F) recommendations for countermeasures,
20 including enhanced intelligence collection, ex-
21 port controls, and international cooperation.

22 (3) FORM.—The assessment shall be submitted
23 in an unclassified form, and may contain a classified
24 annex.

1 (d) INTERAGENCY COORDINATION ON BIO-
2 TECHNOLOGY RISK.—

3 (1) IN GENERAL.—Not later than 180 days
4 after the date of the enactment of this Act, the Sec-
5 retary of Defense, in consultation with the Secretary
6 of State, the Secretary of Commerce, the Secretary
7 of the Treasury, and other appropriate Federal
8 agencies, shall establish monitoring and evaluation
9 mechanisms to conduct risk assessments by con-
10 vening a Biotechnology Risk Contact Group to carry
11 out the duties described in paragraph (2).

12 (2) BIOTECHNOLOGY RISK CONTACT GROUP.—
13 The Biotechnology Risk Assessment Contact Group
14 convened pursuant to paragraph (1) shall—

15 (A) monitor and assess foreign invest-
16 ments, partnerships, and joint ventures in the
17 United States biotechnology sector, with a focus
18 on investments by entities from the People's
19 Republic of China;

20 (B) identify risks to national security
21 posed by such investments, including the poten-
22 tial transfer of sensitive technologies, intellec-
23 tual property, or genomic data;

1 (C) coordinate with the Committee on For-
2 eign Investment in the United States to review
3 biotechnology-related transactions;

4 (D) develop and maintain a database of
5 foreign entities involved in the United States
6 biotechnology sector, including their affiliations
7 with foreign governments or military organiza-
8 tions; and

9 (E) provide annual reports to Congress on
10 foreign activities in the United States bio-
11 technology sector, along with recommendations
12 for mitigation measures.

13 (3) BRIEFING.—Not later than 180 days after
14 the establishment of the Biotechnology Risk Contact
15 Group, and every 90 days thereafter, the Secretary
16 of Defense, in consultation with the Secretary of
17 State, the Secretary of Commerce, and the Secretary
18 of the Treasury, shall brief the appropriate congres-
19 sional committees on the activities of the Group.

20 (e) APPROPRIATE CONGRESSIONAL COMMITTEES DE-
21 FINED.—In this section, the term “appropriate congres-
22 sional committees” means—

23 (1) the Committee on Armed Services, the
24 Committee on Foreign Relations, the Committee on
25 Commerce, Science, and Transportation, and the

1 Committee on Banking, Housing, and Urban Affairs
2 of the Senate; and

3 (2) the Committee on Armed Services, the
4 Committee on Foreign Affairs, the Committee on
5 Energy and Commerce, and the Committee on Fi-
6 nancial Services of the House of Representatives.

